



Getting Great Results with Fenestra Contrast Agents



The Fenestra™ line of imaging products provide flexible, long-lasting contrast enhancement for a wide range of computed tomography imaging applications, including vascular and hepatobiliary anatomy and function.

Vascular Imaging with Fenestra VC and Siemens' MicroCAT II Scanner

This case study provides guidance and recommendations for conducting vascular imaging studies in normal mice with Fenestra VC and Siemens' MicroCAT II microCT scanner. You should note that other examples of the capabilities of Fenestra and a selection of additional case studies are available on the ART website at www.art.ca/en/imaging-agents/.

Animal Model

Strain

C57Bl/6 (31 to 36 g males).

Model

Normal mice.

Animal Preparation

Anesthesia

Mice were anesthetized with an intraperitoneal injection of a mixture of ketamine (80 mg/kg body weight) and xylazine (5 mg/kg body weight), which afforded 45 to 60 minutes of anesthesia. Anesthesia was maintained with quarter dose increments during the duration of the study.

Administration and Dosage

Fenestra VC was injected intravenously into the lateral tail vein of anesthetized mice at a dose of 0.4 ml per 20 g body weight over a period of 30 to 60 seconds. A 1 ml disposable syringe fitted with a 30-gauge needle was used to inject the contrast agent. Prior to injection, the tail vein was immersed in warm water for 30 to 60 seconds to increase blood flow to the tail and dilate the vessels.

NOTE Refer to the ART publication *Using Fenestra Contrast Agents* (PMK-UG001-E) for recommendations and detailed instructions related to dosage, animal preparation, and administration.

Image Acquisition

Equipment

ImTek (now Siemens) MicroCAT II microCT scanner.



Getting Great Results with Fenestra Contrast Agents

Animal Placement

Anesthetized mice were placed on the imaging table in the prone position with heads oriented into the gantry. The desired body region was selected from the scout view as the anatomic landmark for image acquisition.

Settings

The settings selected for this medium resolution contrast-enhanced study were as follows:

X-Ray Camera

Parameter	Setting
Serial CCD Length	2048
Parallel CCD Length	3072
Serial Bin Factor	2
Parallel Bin Factor	2
Exposure Time	750 ms
Warp Correction	Yes
Defect Map Correction	No

X-Ray Tube

Parameter	Setting
X-Ray Voltage	80.0 kVp
Anode Current	500.0 μ A

CT Scan

Parameter	Setting
Rotating Stage Start Position	0.000 degrees
Bed Axis Position	313.863 mm
Bed Height	43.026 mm
Detector Position	0.000 mm
Total Rotation	360 degrees
Number of Rotation Steps	520
Number of Axial Bed Steps	0
Number of Detector Steps	0
Number of Acquired Calibration Exposures	20
Projection Display Period	1
Raw Data	Written to File
Real Time Reconstruction	No
Total Scan Time	11.07 min



Getting Great Results with Fenestra Contrast Agents

Scanner Geometry Setup

Parameter	Setting
Source to Detector Distance	309.600 mm
Source to Center Distance	256.200 mm
Physical Detector Pitch	32.700 μm
Detector Array Height	2048 elements
Detector Array Width	3072 elements
Center Offset	4.7 unbinned detectors

Images were obtained immediately after administration ($T = 0$) with subsequent scans acquired at 15, 30, 60, 120, 180, and 240 minutes post-injection. Beginning at $T = 0$, vascular contrast rapidly increased to a level that was sustained at all time points for the remainder of the study. The liver showed a slight increase in CT density due to its significant vascular supply, while the highly vascular structure of the spleen resulted in a high level of contrast enhancement. After the four-hour time point, vascular contrast enhancement declined gradually as Fenestra VC underwent hepatobiliary elimination.

Data Reconstruction and Visualization

Data Reconstruction

Machine-based reconstruction does not allow for down-sampling of projections prior to reconstruction, as does software-based reconstruction programs. However, down-sampling was unnecessary for the selected resolution in this study.

NOTE Reconstructed image files can be stored as CT or ATT files, which can be exported to a 3D visualization application such as Visage Imaging's Amira software for viewing as axial, coronal, and sagittal images, in addition to a number of other image representations.

Parameter	Setting
Number of Voxels in Volume	512 \times 512 (transaxial) \times 768 (axial)
Voxel Size	100 μm (transaxial) \times 150 μm (axial)
Reconstruction Filter	Shepp-Logan
Reconstruction Algorithm	Fledkamp cone-beam

Data Visualization

Data is routinely imported from reconstruction programs as raw CT image data or as bitmaps windowed to a vascular contrast setting. Data can be viewed in Amira using the Standard Display format with simultaneous display of the axial, coronal, and sagittal images, or as 3D isosurface images that can be manipulated to view anatomic structures with or without orthoslice display of 1, 2, or all 3 of the planar slices. The isosurface image can also be cropped to eliminate extraneous data and saved as an Amira map file, which can accelerate isosurface viewing and save storage space.

Using Amira's image capture feature, planar and 3D images can be captured for presentations or publication purposes, while movies can be created for fly-through of 3D image data sets.



Getting Great Results with Fenestra Contrast Agents

Representative Images

A series of representative images from the study conducted in normal mice using Fenestra VC, and that was obtained with a MicroCAT II scanner, are provided in the figures on the following pages.

Pre-contrast Exam



Figure 1. Non-contrast coronal scan of a male mouse. Poor soft tissue contrast is evident in the thoracic and abdominal cavities. The bright spots observed in the intestines were caused by minerals in the rodent chow that attenuated X-ray energy.

Fenestra VC Exam




Figure 2. Axial, coronal, and sagittal views of a male mouse 15 minutes after IV injection of Fenestra VC. **a.** The axial image depicts both ventricles of the heart, as well as several major vessels in the thoracic cavity. **b.** The coronal image shows the inferior vena cava, the renal veins, additional renal vasculature, as well as several veins



Getting Great Results with Fenestra Contrast Agents

lower in the abdomen. The spleen (seen adjacent to the left kidney) is slightly enhanced due to its high degree of vascularity. **c.** In the sagittal view, the inferior vena cava and a short segment of the portal vein can be seen below the dome of the liver, while the heart, aorta and several other vessels can be seen in the thoracic region.



a.

b.

c.

Figure 3. Coronal and sagittal scans of a male mouse obtained 3 hr after IV administration of Fenestra VC. **a.** Coronal image shows Fenestra VC continued to produce vascular contrast 3 hr after injection, clearly delineating the ventricles and ventricular wall, the aorta, and the carotid arteries in the neck. Small vessels are clearly observed in the liver, which is only slightly enhanced due to the initial elimination of the contrast agent, although the gall bladder has yet to enhance as a result of excretion of the metabolized agent. **b.** This sagittal view shows a major vessel diagonally traversing the liver with a number of smaller vessels seen in cross section. The heart and the aorta are readily visualized as is another vessel, which appears to bifurcate just below the base of the skull. **c.** Sagittal image shows the descending aorta and several other arteries in the abdomen. The heart, aorta, and several additional vessels are seen in the thorax and neck of the mouse. Chow-induced artifacts are evident in the intestines in all three images.



Getting Great Results with Fenestra Contrast Agents




Figure 4. Volumetric representations of vascular enhancement from scans of a male mouse 3 hr after IV administration of Fenestra VC. Fenestra VC produces prolonged vascular contrast enhancement throughout the entire body from a single peripheral injection.

DISCLAIMER: Your results may vary depending on the scanner model and settings, animal strain and sex, injection technique, the specific animal models employed, and other factors. Use of the tips described in this document cannot guarantee success. Some or all of these suggestions may be ineffective or even harmful depending on circumstances. ART has not verified the suggestions contained herein and assumes no liability with respect to their use. Users accept all risks and responsibility for losses, damages, costs, and all other consequences arising directly or indirectly from use of this information.

PMK-UG009-E02

ART is a leading provider of clinical and preclinical optical imaging systems and products.

ART Advanced Research Technologies Inc.
2300 Alfred-Nobel Boulevard
Technoparc Montréal
Montreal (QC), Canada H4S 2A4

T 514.832.0777
F 514.832.0778
E fenestra@art.ca
www.art.ca

© 2011 ART Advanced Research Technologies Inc. All rights reserved. Fenestra is a trademark of ART. Other company and product names may be trademarks of their respective companies and should be noted as such.

